Daily Archives: May 26, 2022
Top studies of 2021 relevant to primary care.
26 May, 2022 | 10:55h | UTCTop studies of 2021 relevant to primary care: From the PEER team – Canadian Family Physician
Study reports first use of antivirals in monkeypox patients.
26 May, 2022 | 11:27h | UTCNews Release: Study reports first use of antivirals in monkeypox patients – Lancet
Original Study: Clinical features and management of human monkeypox: a retrospective observational study in the UK – The Lancet Infectious Diseases
Commentary: Antiviral drug may limit monkeypox symptom duration, infectiousness – CIDRAP
Commentary from one of the author on Twitter (thread – click for more)
https://twitter.com/OutbreakJake/status/1529229623908761601
Cohort Study: Protection and waning of natural and hybrid immunity to SARS-CoV-2.
26 May, 2022 | 11:07h | UTCProtection and Waning of Natural and Hybrid Immunity to SARS-CoV-2 – New England Journal of Medicine
Editorial: Audio Interview: Waning Immunity against Covid-19
Commentary on Twitter
Protection against SARS-CoV-2 waned over time in both vaccinated and previously infected persons; an additional vaccine dose restored protection, find investigators from Israel. https://t.co/617uBmWu8l pic.twitter.com/yiDnBbCuQ5
— NEJM (@NEJM) May 25, 2022
Study Commentary: Long COVID risk falls only slightly after vaccination, huge study shows.
26 May, 2022 | 11:25h | UTCCommentary: Long COVID risk falls only slightly after vaccination, huge study shows – Nature
Original Study: Long COVID after breakthrough SARS-CoV-2 infection – Nature Medicine
Commentary from the author on Twitter (thread – click for more)
The latest from our team in @NatureMedicine
Does vaccination protect from #LongCovid?
Vaccines modestly reduce but do not eliminate risk of Long Covid @VAResearch @vahsrd @WUSTLmed @WUSTLnews @VREFSTL@Biostayan @BCBowe https://t.co/UEexmL8svS
A thread 🧵
— Ziyad Al-Aly, MD (@zalaly) May 25, 2022
Cohort Study: Trajectory of long covid symptoms after covid-19 vaccination.
26 May, 2022 | 11:23h | UTCTrajectory of long covid symptoms after covid-19 vaccination: community based cohort study – The BMJ
Editorial: Are vaccines a potential treatment for long covid? – The BMJ
News Release: Vaccination after SARS-CoV-2 infection linked to a decrease in long covid symptoms – BMJ Newsroom
Commentary on Twitter
LONG COVID: Number of well controlled studies (controls means comparison group of 1) unvaccinated and 2) those who have never had COVID) that show vaccination works to reduce or eliminate long COVID symptoms increasing. BMJ below + biggest from Israel herehttps://t.co/jtZ6aoDmFA https://t.co/n5oDs0Zxe9
— Monica Gandhi MD, MPH (@MonicaGandhi9) May 19, 2022
Test-negative, case–control study: effectiveness of homologous and heterologous Covid-19 boosters against Omicron.
26 May, 2022 | 10:59h | UTC
Navigating financial toxicity in patients with cancer: A multidisciplinary management approach.
26 May, 2022 | 10:57h | UTCRelated:
Not Just Nausea And Vomiting: Cancer Docs Now Worry About ‘Financial Toxicity’ – WBUR
Financial Toxicity and Cancer Treatment (PDQ®) – National Institute of Cancer
The Lancet Series: Urban design, transport, and health.
26 May, 2022 | 10:49h | UTCHomepage: Urban design, transport, and health – The Lancet Global Health
Series:
Commentaries:
Creating healthy and sustainable cities: what gets measured, gets done
Urban design is key to healthy environments for all
Measuring what matters: supporting cities in tackling climate and health challenges
The future is urban: integrated planning policies can enable healthy and sustainable cities
Commentary on Twitter
Delighted to announce the publication of our Series on urban design, transport, and health. Visit the hub page for the full Series, Comments, and added extras: https://t.co/dQrsK4jrGe pic.twitter.com/AAi9BeuRhy
— The Lancet Global Health (@LancetGH) May 11, 2022
Guideline on wound healing interventions to enhance healing of diabetic foot ulcers.
26 May, 2022 | 10:46h | UTC
Characterizing and quantifying low-value diagnostic imaging internationally: a scoping review.
26 May, 2022 | 10:48h | UTC
Position Paper: Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer.
26 May, 2022 | 10:42h | UTC
Guidelines on the management of lumbar spinal stenosis.
26 May, 2022 | 10:44h | UTC
New study looks at heart defect risk in children of people with heart defects.
26 May, 2022 | 10:38h | UTCNews Release: New study looks at heart defect risk in children of people with heart defects – American Heart Association
Original Study: Risk of Congenital Heart Defects in Offspring of Affected Mothers and Fathers – Circulation: Genomic and Precision Medicine
State of the Art Review: Clinical decision support in cardiovascular medicine.
26 May, 2022 | 10:39h | UTCClinical decision support in cardiovascular medicine – The BMJ
Commentary on Twitter
NEW clinical review looks at the evidence on key emerging questions around the development, implementation, and regulation of clinical decision support with a focus on cardiovascular disease https://t.co/hr7Z2jutdZ
— The BMJ (@bmj_latest) May 25, 2022
M-A: Maternal pregnancy outcomes in women with cardiomyopathy.
26 May, 2022 | 10:36h | UTC
Second Revision of the International Staging System (R2-ISS) for overall survival in Multiple Myeloma.
26 May, 2022 | 10:34h | UTC
Phase 1/2 RCT: Safety and efficacy of the mTOR inhibitor, Vistusertib, combined With Anastrozole in patients with hormone receptor−positive recurrent or metastatic endometrial cancer.
26 May, 2022 | 10:30h | UTCSafety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor−Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
https://twitter.com/JAMAOnc/status/1524781949386166272
Systematic Review: Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal pilonidal sinus.
26 May, 2022 | 10:27h | UTC
Commentary on Twitter
https://twitter.com/CochraneWounds/status/1528659470842269696
M-A: Effectiveness and harms of contraceptive counseling and provision interventions for women.
26 May, 2022 | 10:23h | UTCEffectiveness and Harms of Contraceptive Counseling and Provision Interventions for Women: A Systematic Review and Meta-analysis – Annals of Internal Medicine (link to abstract – $ for full-text)
Annals Video Summary: Effectiveness and Harms of Contraceptive Counseling and Provision Interventions for Women: A Systematic Review and Meta-analysis
Commentary: Contraceptive counseling, provision increases use, reduces unintended pregnancy – ACP Internist
Systematic Review: Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.
26 May, 2022 | 10:25h | UTCSummary: Treatment of unintentional drooling of saliva in motor neuron disease – Cochrane Library
Review: The role of peritoneal dialysis in different phases of kidney transplantation.
26 May, 2022 | 10:16h | UTCThe Role of Peritoneal Dialysis in Different Phases of Kidney Transplantation – Kidney360
Adverse effects and Safety in Glaucoma Patients – Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD) – A Delphi Consensus Statement.
26 May, 2022 | 10:14h | UTC
Practical guidance to qualitative research. Part 6: Longitudinal qualitative and mixed-methods approaches for longitudinal and complex health themes in primary care research.
26 May, 2022 | 10:15h | UTCOther articles in the series:
Series: Practical guidance to qualitative research. Part 1: Introduction
Series: Practical guidance to qualitative research. Part 2: Context, research questions and designs
Series: Practical guidance to qualitative research. Part 3: Sampling, data collection and analysis
Series: Practical guidance to qualitative research. Part 4: Trustworthiness and publishing
RCT: Aumolertinib vs. Gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR Exon 19 deletion or L858R mutations.
26 May, 2022 | 10:10h | UTC
Commentary on Twitter
Aumolertinib (a 3rd gen TKI) is effective in the first-line treatment of EGFR-mutant NSCLC-AENEAShttps://t.co/QL6xXptxFa pic.twitter.com/grIbapsxzU
— K Pavithran (@drkpavithran) May 18, 2022
https://creativecommons.org/licenses/by-nc-nd/4.0/
M-A: Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide.
26 May, 2022 | 10:13h | UTCRelated:
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis – Nature Medicine
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)